Home » Topics » Regulatory » EMA

EMA
RSS

Novartis to revise product information for Rasilez in the E.U.

Feb. 20, 2012

Novartis Vaccines and Diagnostics withdraws MAA for Fluad Pediatric

Feb. 17, 2012

GSK withdraws indication extension application for Tyverb

Feb. 17, 2012

CPP-115 receives European orphan drug status

Feb. 14, 2012

Alexza Pharmaceuticals receives first feedback on Adasuve MAA

Feb. 14, 2012

Navidea Biopharmaceuticals receives CHMP advice on Lymphoseek MAA

Feb. 2, 2012

Indication for Gadovist 1.0 is expanded

Jan. 30, 2012

Novartis reflects on accomplishments of 2011

Jan. 30, 2012

CHMP issues opinion on Remicade for ulcerative colitis in children

Jan. 26, 2012

CHMP recommends updating Glivec label in Europe

Jan. 24, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 9, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...